MiniMed Group (NASDAQ:MMED) Price Target Lowered to $22.00 at Wells Fargo & Company

MiniMed Group (NASDAQ:MMED) had its price target lowered by equities researchers at Wells Fargo & Company from $26.00 to $22.00 in a report issued on Thursday,Benzinga reports. The firm presently has an “overweight” rating on the stock. Wells Fargo & Company‘s target price would suggest a potential upside of 54.28% from the company’s previous close.

Other equities research analysts have also issued research reports about the company. The Goldman Sachs Group began coverage on MiniMed Group in a research note on Tuesday, March 31st. They set a “buy” rating and a $24.00 price target for the company. Mizuho started coverage on MiniMed Group in a report on Tuesday, March 31st. They set an “outperform” rating and a $21.00 price objective on the stock. Deutsche Bank Aktiengesellschaft assumed coverage on MiniMed Group in a research report on Tuesday, March 31st. They issued a “buy” rating and a $20.00 target price for the company. Morgan Stanley assumed coverage on shares of MiniMed Group in a research report on Tuesday, March 31st. They set an “overweight” rating and a $19.00 price target on the stock. Finally, Barclays assumed coverage on shares of MiniMed Group in a report on Wednesday, April 1st. They issued an “overweight” rating and a $26.00 price objective for the company. One investment analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, MiniMed Group has an average rating of “Moderate Buy” and a consensus target price of $21.33.

MiniMed Group Stock Performance

Shares of NASDAQ:MMED opened at $14.26 on Thursday. The business has a fifty day moving average of $12.96. MiniMed Group has a one year low of $10.65 and a one year high of $20.48.

MiniMed Group (NASDAQ:MMED) last posted its quarterly earnings data on Wednesday, June 3rd. The company reported ($0.68) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.46). The firm had revenue of $837.00 million for the quarter. The company’s quarterly revenue was up 15.6% compared to the same quarter last year.

MiniMed Group Company Profile

We are a scaled global medical technology company that develops, manufactures, and markets a comprehensive suite of solutions for the management of diabetes. Since our founding more than 40 years ago, we have pioneered groundbreaking innovation and served the needs of our customers across the globe in service of our mission to make every day a better day for people with diabetes. Today, we are the only player in the market that commercializes all parts of an integrated diabetes management system.